RE:RE:LiquiditySorry...I didn't mean to distract (with my "perversions") the 1 or 2 people that are considering buying a couple more shares...
Take some comfort in knowing that there are many days, like today, where there are more buyers stateside than north of the 49th...odd since there can't be many of us that have US cousins that Cdn retailers want to give stock tips to.
They say that word of mouth is the best form of marketing...I'm only sure that it is the case when it's the only form of marketing.
Assuming the requisite F&F circle has been sufficiently expanded and lubricated...any day now...
...I vote for a distribution of Dialco shares to long suffereing EDT longs, in order to (possibly? probably?) immediately double the MC of the combined two trick pony. Then afterwards, we can debate if a sufficient number of boxes have been ticked before giving the average US retailer access to the story....starting with something simple like....oh I don't know...the up-start game-changing competitor to Tablo and NxStage perhaps (each with a MC of $ 3B ish)? Most investors aren't that smart or just don't have the attention span, so simple is good. Sepsis is such a uninteresting & involved topic, until we can finally get that elevator pitch perfected.
Here's a start...on the uninteresting part....
Did you know there is a small Cdn Company running a Phase 3 bTrial, with favorable (E.D. US spelling so we don't lose anybody) parameters that will potentially bring to the market the first new treatment for Sepsis in more than 30 years. What's Sepsis you ask? It's a condition, characterized by endotoxemia or an infection leading to an inflammatory response that can kill up to one third of Sepsis sufferors. Sepsis kills upwards of 11 million people world-wide each and every year (more than 3 times the number of Covid-19 deaths so far, and twice the number of Jewish people exterminated in WWII). And this small Cdn Company has secured the rights to this new treatment for NA until at least 2034. The treatment (blood filtration of endotoxins) has been used safely on over 300,000 people in Japan and parts of Europe. And there is mounting real-world evidence of its efficacy and its potential for use beyond just the treatment of Sepis. This end-stage confirmatory Trial, called Tigris, has been materially backed/endorsed by two very large multi-billion dollar healthcare Companies (Toray and Baxter) and two of the world's leading experts and Key Opinion Leaders in the area of Nephrology, Kidney Injury and blood filtration.
...Ohh and as a bonus, this company has another group of end-stage products that directly addresses another $ 5B + US market opportunity, through innovation and game-changing technology.
Too long? Better we create two groups of shareholders, and have one pitch to each group.
MM